Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
AI Therapeutics is a clinical-stage biopharmaceutical company that has created an artificial intelligence-driven drug development platform for matching drugs to new indications.
High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a potentially fatal disease caused by obstruction of blood flow in the lungs.
Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).
Scientists have identified a molecular pathway that contributes to the development of pulmonary arterial hypertension, a severe, often fatal condition that has no cure.
Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with MannKind Corporation, a biopharmaceutical company focused on inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.
New University of Alberta research is paving the way for the first medical treatment to help protect people from cardiovascular disease by boosting the body's natural defenses.
Patients with left-sided heart failure who get implanted devices to improve the pumping of their hearts may be more likely to develop heart failure on the opposite side of their hearts if they are pre-treated with off-label selective vasodilator drugs, according to new research published in Circulation: Heart Failure, an American Heart Association journal.
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine today announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension, to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.
Novel studies from around the world showing cutting-edge clinical use of cardiovascular magnetic resonance will be presented at EuroCMR 2019, a meeting of the European Association of Cardiovascular Imaging, a branch of the European Society of Cardiology.
Trio Health today announced the launch of the TH-PAH database for patients with Pulmonary Arterial Hypertension.
A new biomarker that could be used to provide earlier diagnosis for a life-limiting lung condition has been identified by researchers at the University of Bradford.
For some older people, the joy of sex may be tempered by financial concerns: Can they afford the medications they need to improve their experience between the sheets?
The American College of Chest Physicians announced the publication of updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Is it safe for women with heart disease to become pregnant? Usually, according to ten-year results from the ROPAC registry reported in a late breaking science session today at ESC Congress 2018.
Pregnant women with heart disease should give birth at no later than 40 weeks gestation. That is one of the recommendations in the 2018 European Society of Cardiology Guidelines for the management of cardiovascular diseases during pregnancy published online today in European Heart Journal, and on the ESC website.
Scientists at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago took a major step toward developing a new treatment for pulmonary arterial hypertension, a severe lung disease with a five-year survival rate of 50 percent.
The new journal Cardiovascular Innovations and Applications has just published the first issue of Volume 3. This is a Special Issue on Adult Congenital Heart Disease with Guest Editor Diego Moguillansky of the University of Florida Medical School.
New and better ways to fight hypertension and low blood pressure may be in the offing, thanks to the National University of Singapore scientists' discovery of how our blood pressure is controlled.
The ATS Foundation is pleased to announce a new ATS Foundation/Insmed Research Award in Non-Tuberculous Mycobacteria Lung Disease, which will provide one year of funding support in the amount of $50,000.